FIG 7.

Antiviral efficacy of NITD008 in BLT-NOD/SCID mice. Humanized mice were inoculated i.v. with 1 × 10⁶ TCID₅₀ of DENV-2 Col, and antiviral efficacy was evaluated by using two different protocols. (A) The antiviral compound NITD008 was administered i.p. (to 10 mice) at the indicated concentrations immediately before viral inoculation, and dosing continued every 12 h for 7 days. Equal volumes of the DMSO vehicle were administered to the control group (6 mice). (B) Antiviral treatment was started at day 2 postinfection. Two groups of mice (n = 5 per group) were dosed i.p. twice a day with the indicated amount of the antiviral agent NITD008. The control group (9 mice) was treated with DMSO twice a day. Mice were bled at the indicated times postinfection, and viral RNA was extracted from plasma and quantified by qRT-PCR. Results are presented as copies of viral RNA per ml of plasma. The gray box indicates the duration of antiviral treatment. Based on Student's t test: **, P ≤ 0.005; *, P ≤ 0.05.